2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort